Pancreatic cancer is the third leading cause of cancer related death, and is predicted to be the second within a decade. The overall five-year survival is less than 5%, one of the lowest among all cancer types, and this survival rate has not changed for more than 50 years. Recent large scale genomic studies demonstrated vast inter-tumoural heterogeneity, which may have contributed to the challenges in therapeutic development. In this talk, the key results of recent genomic studies will be presented, and novel therapeutic strategies using a personalised approach will be discussed.

References: Biankin et al, Nature 2012; Waddell et al, Nature 2015; Biankin et al, Nature 2015; Bailey et al, Nature 2016